Cargando…

Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community

Background: In this work, we aimed to evaluate antibody-response longevity to SARS-CoV-2 infection and/or vaccination in one of the Greek communities that was worst hit by the pandemic, Deskati, five months after a previous serosurveillance and nine months after the pandemic wave initiation (October...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotsiou, Ourania S., Papagiannis, Dimitrios, Fradelos, Evangelos C., Siachpazidou, Dimitra I., Perlepe, Garifallia, Miziou, Angeliki, Kyritsis, Athanasios, Vavougios, George D., Kalantzis, Georgios, Gourgoulianis, Konstantinos I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744770/
https://www.ncbi.nlm.nih.gov/pubmed/35010667
http://dx.doi.org/10.3390/ijerph19010407
_version_ 1784630188189941760
author Kotsiou, Ourania S.
Papagiannis, Dimitrios
Fradelos, Evangelos C.
Siachpazidou, Dimitra I.
Perlepe, Garifallia
Miziou, Angeliki
Kyritsis, Athanasios
Vavougios, George D.
Kalantzis, Georgios
Gourgoulianis, Konstantinos I.
author_facet Kotsiou, Ourania S.
Papagiannis, Dimitrios
Fradelos, Evangelos C.
Siachpazidou, Dimitra I.
Perlepe, Garifallia
Miziou, Angeliki
Kyritsis, Athanasios
Vavougios, George D.
Kalantzis, Georgios
Gourgoulianis, Konstantinos I.
author_sort Kotsiou, Ourania S.
collection PubMed
description Background: In this work, we aimed to evaluate antibody-response longevity to SARS-CoV-2 infection and/or vaccination in one of the Greek communities that was worst hit by the pandemic, Deskati, five months after a previous serosurveillance and nine months after the pandemic wave initiation (October 2020). Methods: The SARS-CoV-2 IgG II Quant method (Architect, Abbott, IL, USA) was used for antibody testing. Results: A total of 69 subjects, who previously tested positive or negative for COVID-19 antibodies, participated in the study. We found that 48% of participants turned positive due to vaccination. 27% of participants were both previously infected and vaccinated. However, all previously infected participants retained antibodies to the virus, irrespective of their vaccination status. The antibody titers were significantly higher in previously infected participants that had been vaccinated than those who were unvaccinated and in those that had been previously hospitalized for COVID-19 than those with mild disease. Conclusions: Antibody responses to SARS-CoV-2 infection were maintained nine months after the pandemic. Vaccination alone had generated an immune response in almost half of the population. Higher antibody titers were found in the case of vaccination in previously infected subjects and especially in those with severe disease leading to hospitalization.
format Online
Article
Text
id pubmed-8744770
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87447702022-01-11 Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community Kotsiou, Ourania S. Papagiannis, Dimitrios Fradelos, Evangelos C. Siachpazidou, Dimitra I. Perlepe, Garifallia Miziou, Angeliki Kyritsis, Athanasios Vavougios, George D. Kalantzis, Georgios Gourgoulianis, Konstantinos I. Int J Environ Res Public Health Article Background: In this work, we aimed to evaluate antibody-response longevity to SARS-CoV-2 infection and/or vaccination in one of the Greek communities that was worst hit by the pandemic, Deskati, five months after a previous serosurveillance and nine months after the pandemic wave initiation (October 2020). Methods: The SARS-CoV-2 IgG II Quant method (Architect, Abbott, IL, USA) was used for antibody testing. Results: A total of 69 subjects, who previously tested positive or negative for COVID-19 antibodies, participated in the study. We found that 48% of participants turned positive due to vaccination. 27% of participants were both previously infected and vaccinated. However, all previously infected participants retained antibodies to the virus, irrespective of their vaccination status. The antibody titers were significantly higher in previously infected participants that had been vaccinated than those who were unvaccinated and in those that had been previously hospitalized for COVID-19 than those with mild disease. Conclusions: Antibody responses to SARS-CoV-2 infection were maintained nine months after the pandemic. Vaccination alone had generated an immune response in almost half of the population. Higher antibody titers were found in the case of vaccination in previously infected subjects and especially in those with severe disease leading to hospitalization. MDPI 2021-12-31 /pmc/articles/PMC8744770/ /pubmed/35010667 http://dx.doi.org/10.3390/ijerph19010407 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kotsiou, Ourania S.
Papagiannis, Dimitrios
Fradelos, Evangelos C.
Siachpazidou, Dimitra I.
Perlepe, Garifallia
Miziou, Angeliki
Kyritsis, Athanasios
Vavougios, George D.
Kalantzis, Georgios
Gourgoulianis, Konstantinos I.
Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community
title Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community
title_full Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community
title_fullStr Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community
title_full_unstemmed Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community
title_short Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community
title_sort defining antibody seroprevalence and duration of humoral responses to sars-cov-2 infection and/or vaccination in a greek community
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744770/
https://www.ncbi.nlm.nih.gov/pubmed/35010667
http://dx.doi.org/10.3390/ijerph19010407
work_keys_str_mv AT kotsiououranias definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT papagiannisdimitrios definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT fradelosevangelosc definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT siachpazidoudimitrai definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT perlepegarifallia definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT miziouangeliki definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT kyritsisathanasios definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT vavougiosgeorged definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT kalantzisgeorgios definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity
AT gourgoulianiskonstantinosi definingantibodyseroprevalenceanddurationofhumoralresponsestosarscov2infectionandorvaccinationinagreekcommunity